Last reviewed · How we verify
NCT04781634
a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL
Phase 1, PHASE2 trial testing CD19 and CD22 targeted prime CAR-T cells in B-ALL in 40 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | Chongqing Precision Biotech Co., Ltd |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 7 March 2021 |
| Primary completion | 31 December 2026 |
| Estimated completion | 1 July 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- CD19 and CD22 targeted prime CAR-T cells
Conditions studied
- B-ALL — all drugs for B-ALL →
Sponsor
Chongqing Precision Biotech Co., Ltd — full company profile →
Who can join
Adults 2 to 75, any sex, with B-ALL. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single arm study to evaluate the efficacy and safety of CD19 and CD22 targeted prime CAR-T cells therapy for patients with relapsed/refractory B -ALL
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeting CD22 for the Treatment of B-Cell Malignancies.
Shah NN, Sokol L. · · 2021 · cited 42× · PMID 34262884 · DOI 10.2147/itt.s288546 -
Next-generation chimeric antigen receptors for T- and natural killer-cell therapies against cancer.
Li Y, Rezvani K, Rafei H. · · 2023 · cited 29× · PMID 37548050 · DOI 10.1111/imr.13255 -
CAR T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.
Saleh K, Pasquier F, Bigenwald C, De Botton S, et al · · 2023 · cited 11× · PMID 37959347 · DOI 10.3390/jcm12216883
Verify or expand the search:
- PubMed search for NCT04781634
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for B-ALL
Currently open trials in the same condition.
- NCT06785324 — Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL) · NA · recruiting
- NCT06689917 — JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia · NA · recruiting
- NCT07244406 — Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL · Phase 2 · recruiting
- NCT06911710 — The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors · Phase 1, PHASE2 · recruiting
- NCT06678282 — JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia · NA · recruiting
Other Chongqing Precision Biotech Co., Ltd trials
Trials by the same sponsor.
- NCT07181720 — CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors · Phase 1 · recruiting
- NCT07179692 — CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors · Phase 1 · recruiting
- NCT07184450 — Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases · Phase 1 · recruiting
- NCT07239323 — In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies · Phase 1 · recruiting
- NCT06892145 — Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04781634 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chongqing Precision Biotech Co., Ltd
- Last refreshed: 25 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04781634.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing